Sign in
Taking peoplePhase 2

Therapeutic Plasma Exchange in Septic Shock: A Pilot Study

Key facts

Who runs it
University of Manitoba
Where
Canada11 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
1 Jun 2023
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Therapeutic Plasma Exchange
Record updated
17 August 2025

Who can take part

Age
16 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Other criteria

  • Eligible patients must be admitted to an ICU and must meet all of the following inclusion criteria:
  • ≥ 16 years of age
  • Refractory hypotension documented within 48 hours prior to enrollment requiring the institution and ongoing use of vasopressor agents (phenylephrine, norepinephrine, vasopressin, epinephrine, midodrine or dopamine >5 mcg/kg/min) at enrollment. Refractory hypotension is defined as a systolic blood pressure (SBP) less than 90 mmHg, or SBP less than 30 mmHg below baseline, or a mean arterial blood pressure less than 65 mmHg, despite adequate fluid resuscitation
  • Capacity to initiate plasma exchange with 48 hours of vasopressor initiation
  • At least 1 other new organ dysfunction (in addition to refractory hypotension), defined by the following at the time of enrollment:; Creatinine ≥1.5x the known baseline creatinine within 7 days, or ≥ 26.5 µmol/l increase in 48 hours,; Need for invasive mechanical ventilation or a P/F ratio <250; Platelets <100 x109/L, or a drop of 50 x109/L in the 3 days prior to enrollment; Arterial pH < 7.30 or base deficit > 5 mmol/L in association with a lactate >/= to 3.0 mmol/L
  • Known or suspected infection; 2.4.3 Exclusion criteria; We will exclude patients who have any one of the following criteria at the time of enrollment:
  • Consent declined (refusal from patient, SDM, or physician)
  • Clinically apparent alternate causes for shock (cardiogenic, hemorrhagic, obstructive, neurogenic or anaphylactic)
  • Terminal illness with a life expectancy of less than 3 months
  • Are pregnant

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigators propose to conduct a multi-center randomized pilot feasibility trial comparing therapeutic plasma exchange to standard of care in patients diagnosed with septic shock.

The 2 groups in the trial

  • Treatment ArmTreatment being tested

    Participants randomized to the Treatment Arm will received 1.0 plasma exchanges daily until discontinuation of vasopressors, death or to a maximum of 5 daily treatments. Solvent detergent plasma (SDP) or frozen plasma (FP) depending on availability will be used as the replacement fluid.

    Treatment: Therapeutic Plasma Exchange

  • Standard of Care ArmNo study treatment, for comparison

    Participants randomized to the Control Arm will receive standard of care for the treatment of septic shock in accordance with local practice and informed by national and international guidelines.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 August 2025